Aldeyra Therapeutics, Inc.
NASDAQ:ALDXBiotechnology
+$0.06 today
- Market cap
- $54.28M
- Beta
- 1.19
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$0.45
Volume 1.45M
Average 2.13M
ALDX Operating Cash Flow
Cash generated by the company's core business operations during the period.
Aldeyra Therapeutics, Inc.NASDAQ: ALDX
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow declines year over year
Q1 FY2026 operating cash flow of $5.11M (cash outflow) fell 59.0% year over year, behind the -43.1% change in trailing-twelve-month operating cash flow. Sequentially, it fell 3.6% from the prior quarter. Over 3 fiscal years it compounded at -16.2% a year.
Context
- Operating cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -59.0% toward the trailing-twelve-month pace of -43.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (33.35M) USD
- Year-over-year change
- +22.8%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.35M) | +22.8% |
| FY2024 | 2024-12-31 | (43.21M) | -42.5% |
| FY2023 | 2023-12-31 | (30.33M) | +46.5% |
| FY2022 | 2022-12-31 | (56.64M) | -33.1% |
| FY2021 | 2021-12-31 | (42.56M) | — |
Operating Cash Flow vs competitors
How ALDX compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -43.1% is the 8th highest of 10, against a peer median of +16.1%.
- Over three fiscal years its annual growth of -16.2% compares with a peer median of +6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $150.39M USD | +12.5% | +62.1% | — | |
| LTM Dec 2025 | CHF 69.2M CHF | -205.1% | -3.5% | 1936.8% | |
| LTM Mar 2026 | $65.57M USD | — | +3.0% | 7115.1% | |
| LTM Mar 2026 | $62.3M USD | +17.6% | +36.4% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $57.17M USD | +46.0% | +40.1% | — |
| LTM Mar 2026 | $47.73M USD | +75.5% | +6.8% | — | |
| LTM Mar 2026 | $37.91M USD | -230.1% | -22.9% | 55.7% | |
| LTM Mar 2026 | $26.95M USD | -18.7% | -14.1% | 5390.8% | |
| LTM Mar 2026 | $25.99M USD | -43.1% | -16.2% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | $25.89M USD | +16.1% | +92.0% | 323650.0% |
| LTM Mar 2026 | $25.51M USD | +182.6% | — | 11.9% | |
| Peer median (excluding ALDX) | — | +16.1% | +6.8% | 3663.8% | |
Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Depreciation & Amortization | 264.18K | 258.71K | 262.78K | 249.62K | 251.99K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.11M | 8.29M | 5.75M | 7.97M | 6.09M |
| Change in Working Capital | 7.44M | (3.44M) | 861.18K | 5.91M | (5.18M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 638.06K | (886.08K) | 1.2M | (1.16M) | (21.99K) |
| Other Working Capital | 6.8M | (2.56M) | (343.25K) | 7.07M | (5.16M) |
| Other Non-Cash Items | 409.47K | 283.91K | 339.65K | (1.49M) | (664.43K) |
| Operating Cash Flow | (42.56M) | (56.64M) | (30.33M) | (43.21M) | (33.35M) |
| Capital Expenditures | (7.81K) | (16.32K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 16.32K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (92.94M) | 0 | (96.92M) | (40.26M) |
| Sales of Investments | 0 | 63M | 30M | 52M | 88M |
| Other Investing Activities | 0 | (16.32K) | 0 | 0 | 0 |
| Investing Cash Flow | (7.81K) | (29.95M) | 30M | (44.92M) | 47.74M |
| Debt Repayment | 0 | 0 | (1.04M) | (292.5K) | 0 |
| Common Stock Issued | 189.81M | 1.22M | 305.23K | 121.08K | 1.12M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.68M | 0 | (532.95K) | 0 | (444) |
| Financing Cash Flow | 194.5M | 1.22M | (1.27M) | (171.42K) | 1.12M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 151.93M | (85.37M) | (1.6M) | (88.3M) | 15.51M |
| Free Cash Flow | (42.56M) | (56.65M) | (30.33M) | (43.21M) | (33.35M) |
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.